Dengue vaccines approach the finish line

被引:63
作者
Edelman, Robert [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA
关键词
D O I
10.1086/518148
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The spread of dengue virus (DV) via its Aedes mosquito vector throughout most of the tropics has led to a worldwide resurgence of epidemic dengue, including dengue hemorrhagic fever. For the first time in 60 years, the pipeline of dengue vaccines looks promising. Strains of each of the 4 DV serotypes, attenuated by passage in tissue culture or by recombinant DNA technology, have been formulated into tetravalent vaccines and have entered successful phase 1 and 2 clinical trials in the United States and Southeast Asia. Antibody-dependent enhancement of wild-type DV infections by the vaccine represents a unique safety issue, which is under investigation. The Pediatric Dengue Vaccine Initiative (funded by the Bill and Melinda Gates Foundation), the World Health Organization, industry, the US military, and governments of tropical countries are collaborating to accelerate dengue vaccine development and phase 3 vaccine efficacy trials in countries where dengue is endemic. A protective tetravalent vaccine must be licensed soon if dengue is to be brought under control.
引用
收藏
页码:S56 / S60
页数:5
相关论文
共 31 条
[1]   Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement [J].
Avirutnan, P ;
Punyadee, N ;
Noisakran, S ;
Komoltri, C ;
Thiemmeca, S ;
Auethavornanan, K ;
Jairungsri, A ;
Kanlaya, R ;
Tangthawornchaikul, N ;
Puttikhunt, C ;
Pattanakitsakul, SN ;
Yenchitsomanus, PT ;
Mongkolsapaya, J ;
Kasinrerk, W ;
Sittisombut, N ;
Husmann, M ;
Blettner, M ;
Vasanawathana, S ;
Bhakdi, S ;
Malasit, P .
JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (08) :1078-1088
[2]   Live attenuated tetravalent dengue vaccine [J].
Bhamarapravati, N ;
Sutee, Y .
VACCINE, 2000, 18 :44-47
[3]  
*CTR DIS CONTR PRE, 2003, WORLD DISTR DENG 200
[4]   Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries [J].
DeRoeck, D ;
Deen, J ;
Clemens, JD .
VACCINE, 2003, 22 (01) :121-129
[5]   rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers [J].
Durbin, AP ;
Whitehead, SS ;
McArthur, J ;
Perreault, JR ;
Blaney, JE ;
Thumar, B ;
Murphy, BR ;
Karron, RA .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05) :710-718
[6]   Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region [J].
Durbin, AP ;
Karron, RA ;
Sun, W ;
Vaughn, DW ;
Reynolds, MJ ;
Perreault, JR ;
Thumar, B ;
Men, R ;
Lai, CJ ;
Elkins, WR ;
Chanock, RM ;
Murphy, BR ;
Whitehead, SS .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 65 (05) :405-413
[7]   Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine [J].
Edelman, R ;
Wasserman, SS ;
Bodison, SA ;
Putnak, RJ ;
Eckels, KH ;
Tang, D ;
Kanesa-Thasan, N ;
Vaughn, DW ;
Innis, BL ;
Sun, W .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 69 (06) :48-60
[8]   Spectrum of disease and relation to place of exposure among ill returned travelers [J].
Freedman, DO ;
Weld, LH ;
Kozarsky, PE ;
Fisk, T ;
Robins, R ;
von Sonnenburg, F ;
Keystone, JS ;
Pandey, P ;
Cetron, MS .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (02) :119-130
[9]  
Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
[10]   Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity [J].
Guirakhoo, Farshad ;
Kitchener, Scott ;
Morrison, Dennis ;
Forrat, Remi ;
McCarthy, Karen ;
Nichols, Richard ;
Yoksan, Sutee ;
Duan, Xiaochu ;
Ermak, Thomas H. ;
Kanesa-Thasan, Niranjian ;
Bedford, Philip ;
Lang, Jean ;
Quentin-Millet, Marie-Jose ;
Monath, Thomas P. .
HUMAN VACCINES, 2006, 2 (02) :60-67